IGF1R and hepatocellular carcinoma: To examine whether the combination of either niclosamide or linsitinib (p-IGF1R inhibitor) with sorafenib can suppress tumor growth in sorafenib-resistant HCC cells in vivo, tumor-bearing NOD-SCID mice were treated with sorafenib (30 mg/kg) for 1 week.